×
Alcon Receivables 2019-2024 | ALC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Alcon receivables for the quarter ending June 30, 2024 were
$1.849B
, a
0.93% increase
year-over-year.
Alcon receivables for 2023 were
$1.804B
, a
7% increase
from 2022.
Alcon receivables for 2022 were
$1.686B
, a
12.03% increase
from 2021.
Alcon receivables for 2021 were
$1.505B
, a
8.9% increase
from 2020.
View More
Alcon Receivables 2019-2024 | ALC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Alcon receivables for 2023 were
$1.804B
, a
7% increase
from 2022.
Alcon receivables for 2022 were
$1.686B
, a
12.03% increase
from 2021.
Alcon receivables for 2021 were
$1.505B
, a
8.9% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Thermo Fisher Scientific (TMO)
$212.6B
Intuitive Surgical (ISRG)
$186.7B
IQVIA Holdings (IQV)
$39.5B
Edwards Lifesciences (EW)
$38.8B
IDEXX Laboratories (IDXX)
$35.5B
DexCom (DXCM)
$26.9B
Waters (WAT)
$22.9B
SONOVA HOLDING (SONVY)
$22B
STERIS (STE)
$21.3B
Hologic (HOLX)
$18.4B
Fresenius Medical Care AG KGaA (FMS)
$12.5B
Sysmex ADR (SSMXY)
$12.4B
Globus Medical (GMED)
$11.1B
Teleflex (TFX)
$9.2B
Penumbra (PEN)
$8.9B
Masimo (MASI)
$8.6B
Glaukos (GKOS)
$7.7B
PROCEPT BioRobotics (PRCT)
$5B
Integer Holdings (ITGR)
$4.5B
Inari Medical (NARI)
$3B
TransMedics (TMDX)
$2.9B
Veracyte (VCYT)
$2.9B
LivaNova (LIVN)
$2.8B
Nihon Kohden (NHNKY)
$2.5B
Elekta AB (EKTAY)
$2.3B
Tandem Diabetes Care (TNDM)
$2.2B
Integra LifeSciences Holdings (IART)
$2B
RxSight (RXST)
$1.9B
Alphatec Holdings (ATEC)
$1.3B
Artivion (AORT)
$1.2B